NSE: AJANTPHARM | BSE: 532331

Expensive Performer

Download real time

3396.50 54.10 (1.62%)

45.78% Gain from 52W Low

111.2K NSE+BSE Volume

NSE 29 Jul, 2026 3:31 PM (IST)

42,426.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Ajanta Pharma is on 30 Jul 2026 for the purpose of Quarterly Results & Interim Dividend See details

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

06 May 2026

3396.50

1.62%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 26 new launches over the last 12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 15 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launch. Asia branded witnessed negative growth due to geopolitical...

Ajanta Pharma has gained 24.95% in the last 6 Months

Ajanta Pharma Ltd.

06 May 2026

3396.50

1.62%

Ajanta Pharma (AJP IN) Q4FY26 Result Update Strong FY27 revenue guidance BUY

Buy: Ajanta Pharma Ltd.

Target

Prabhudas Lilladhar

Guided high teen revenue growth for FY27E. Capex guidance of INR 4bn in FY27E. AJP's Q4FY26 EBITDA grew strongly by 26% YoY (INR3.75bn; 26.4% OPM) which was 15% above our estimates. The beat was aided by higher US revenues and margins. The recent in-licensing agreement with Biocon for marketing semaglutide in 26 countries across RoW markets is good fit given its strong existing franchise across these markets. Further AJP's play on high growth branded generics (BGx) market spread across India, Asia and Africa which contributed 70% to total revenue in FY26. Strong annual free...

Promoters pledged 4.59% of shares in last quarter. Total pledge stands at 22.53% of promoter holdings

Ajanta Pharma Ltd.

06 May 2026

3396.50

1.62%

Ajanta Pharma (BUY): Strong Earnings; FY27 to be healthier than FY26

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT grew by 15.7%/6.8%/21.5% above our estimates. Tax rate reported at 23% vs expected 25.3%

Ajanta Pharma Ltd. has an average target of 3416.75 from 4 brokers.

Ajanta Pharma Ltd.

05 May 2026

3396.50

1.62%

Strong beat on our 4Q estimates; robust outlook

Buy: Ajanta Pharma Ltd.

Motilal Oswal

Ajanta Pharma (AJP) delivered a better-than-expected 4QFY26, with a 10%/17%/21% beat on our revenue/EBITDA/PAT estimates.

Ajanta Pharma has gained 23.24% in the last 3 Months

Ajanta Pharma Ltd.

01 Feb 2026

3396.50

1.62%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 16 new launches over the last 9-12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 9-12 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launches. Asia branded on the other hand witnessed...

Promoters pledged 4.59% of shares in last quarter. Total pledge stands at 22.53% of promoter holdings

Ajanta Pharma Ltd.

31 Jan 2026

3396.50

1.62%

Ajanta Pharma (BUY): Healthy earnings momentum to continue

Buy: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 7%/12% and 5.6% above our estimates driven by beat across regions. EBITDA margin 130 bps above our estimates

Ajanta Pharma has gained 23.24% in the last 3 Months

Ajanta Pharma Ltd.

30 Jan 2026

3396.50

1.62%

Execution drives earnings beat

buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) posted a better-than-expected financial performance in 3QFY26, with 5%/7%/5% beat on revenue/EBITDA/PAT. AJP saw superior execution in Africa, US and domestic formulation (DF), which was offset to some extent by subdued performance in Asia.

Ajanta Pharma has gained 23.24% in the last 3 Months

Ajanta Pharma Ltd.

29 Dec 2025, 12:00AM

3396.50

1.62%

Branded generics playbook fires; semaglutide adds a new growth leg

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP is implementing multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa to sustain robust industry outperformance.

Ajanta Pharma has gained 24.95% in the last 6 Months

Ajanta Pharma Ltd.

04 Nov 2025

3396.50

1.62%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Q2FY26- Momentum driven by US and India Business - Revenues grew ~14% YoY to 1354 crore driven by US and India branded business which grew ~48% / ~12% to 344 crore and 432 crore, respectively. Other branded businesses such as Asia and Africa witnessed the growth of 5% / 4% (on higher base) to 310 crore and 221 crore, respectively. On the operational front, EBITDA grew 5.4% YoY to ~328 crore (excluding forex losses of 41 crore, 9 % growth to ~369 crore) with margins at 24.2%...